News · 26 weeks46+13%
2026-03-012026-08-23
Mix2490d
- Insider13(54%)
- Other4(17%)
- SEC Filings4(17%)
- Earnings2(8%)
- Analyst1(4%)
Latest news
25 items- PRTearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye DiseaseMENLO PARK, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies intended to transform care and improve patients' lives, today announced that, effective August 18, 2026, the U.S. Food and Drug Administration (FDA) updated the TearCare® System (TearCare) Indications for Use to state: "The Sight Sciences TearCare System is a thermal-activated gland expression therapy that improves meibomian gland function in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), when used in conjunction with manual expression of the meibom
- INSIDERChief Legal Officer Rashid Kashif was granted 181,818 shares (SEC Form 4)4 - Sight Sciences, Inc. (0001531177) (Issuer)
- INSIDERSEC Form 3 filed by new insider Rashid Kashif3 - Sight Sciences, Inc. (0001531177) (Issuer)
- SECSight Sciences Inc. filed SEC Form 8-K: Leadership Update8-K - Sight Sciences, Inc. (0001531177) (Filer)
- SECSEC Form 10-Q filed by Sight Sciences Inc.10-Q - Sight Sciences, Inc. (0001531177) (Filer)
- SECSight Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Sight Sciences, Inc. (0001531177) (Filer)
- PRSight Sciences Reports Second Quarter 2026 Financial ResultsMENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the second quarter ended June 30, 2026, raised its revenue guidance and reduced its adjusted operating expense guidance, both for full year 2026. Recent Financial and Business Highlights Second quarter revenue of $23.4 million, a 20% increase compared to $19.6 million in the second quarter of 2025. Interventional Glaucoma (IG) revenue of $20.7 million, an 8% increa
- PRSight Sciences Announces Aetna Coverage for OMNI and SION Surgical SystemsMENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform eyecare and improve patients’ lives, today announced that Aetna, Inc.’s (Aetna) updated Glaucoma Surgery Policy for its commercial plans now recognizes the OMNI® Surgical System (OMNI) and the SION® Surgical Instrument (SION) as medically necessary for the treatment of mild-to-moderate open-angle glaucoma when specified clinical criteria are met, establishing coverage of Sight Sciences’ interventional glaucoma technologies. "We are pleas
- PRSight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical SystemMENLO PARK, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies intended to transform eye care and improve patients' lives, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the OMNI® Ultra Surgical System (OMNI Ultra) for canaloplasty followed by trabeculotomy for the reduction of intraocular pressure (IOP) in adult patients with primary open-angle glaucoma (POAG). Key Features of OMNI Ultra Comprehensive implant-free intervention: Addresses all three known areas of outflow resistance through a single, clear corneal microincis
- ANALYSTUBS resumed coverage on Sight Sciences with a new price targetUBS resumed coverage of Sight Sciences with a rating of Buy and set a new price target of $7.00
- PRSight Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026MENLO PARK, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the second quarter ended June 30, 2026, after the market close on Wednesday, August 5, 2026. The Company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at
- INSIDERChief Legal Officer Hayden Jeremy B. sold $70,133 worth of shares (12,733 units at $5.51), decreasing direct ownership by 3% to 357,037 units (SEC Form 4)4 - Sight Sciences, Inc. (0001531177) (Issuer)
- INSIDERChief Financial Officer Rodberg James sold $36,995 worth of shares (6,902 units at $5.36), decreasing direct ownership by 3% to 224,037 units (SEC Form 4)4 - Sight Sciences, Inc. (0001531177) (Issuer)
- INSIDERChief Technology Officer Badawi David sold $40,858 worth of shares (7,418 units at $5.51), decreasing direct ownership by 0.37% to 1,982,872 units (SEC Form 4)4 - Sight Sciences, Inc. (0001531177) (Issuer)
- INSIDEREVP, Operations & R&D Taylor Brenton sold $15,333 worth of shares (2,829 units at $5.42), decreasing direct ownership by 1% to 264,978 units (SEC Form 4)4 - Sight Sciences, Inc. (0001531177) (Issuer)
- INSIDERChief Operating Officer Bauerlein Alison sold $129,626 worth of shares (24,184 units at $5.36), decreasing direct ownership by 4% to 664,709 units (SEC Form 4)4 - Sight Sciences, Inc. (0001531177) (Issuer)
- INSIDERPresident and CEO Badawi Paul sold $155,467 worth of shares (28,684 units at $5.42), decreasing direct ownership by 0.47% to 6,122,472 units (SEC Form 4)4 - Sight Sciences, Inc. (0001531177) (Issuer)
- INSIDERDirector Fountain Tamara was granted 28,261 shares, increasing direct ownership by 35% to 109,650 units (SEC Form 4)4 - Sight Sciences, Inc. (0001531177) (Issuer)
- INSIDERDirector Encrantz Staffan was granted 28,261 shares, increasing direct ownership by 2% to 1,420,183 units (SEC Form 4)4 - Sight Sciences, Inc. (0001531177) (Issuer)
- INSIDERDirector Burbach Gerhard F was granted 28,261 shares, increasing direct ownership by 30% to 123,207 units (SEC Form 4)4 - Sight Sciences, Inc. (0001531177) (Issuer)
- INSIDERDirector Zurbay Donald was granted 28,261 shares, increasing direct ownership by 17% to 193,613 units (SEC Form 4)4 - Sight Sciences, Inc. (0001531177) (Issuer)
- INSIDERDirector Mazzacco Catherine was granted 28,261 shares, increasing direct ownership by 69% to 69,276 units (SEC Form 4)4 - Sight Sciences, Inc. (0001531177) (Issuer)
- SECSight Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Sight Sciences, Inc. (0001531177) (Filer)
- SECSEC Form SD filed by Sight Sciences Inc.SD - Sight Sciences, Inc. (0001531177) (Filer)
- INSIDERChief Operating Officer Bauerlein Alison sold $65,167 worth of shares (12,728 units at $5.12), decreasing direct ownership by 2% to 688,893 units (SEC Form 4)4 - Sight Sciences, Inc. (0001531177) (Issuer)
SGHT FAQ
7 questionsWhat does Sight Sciences Inc. do?
Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology, for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals...Where does SGHT stock trade?
Sight Sciences Inc. (SGHT) is listed on NASDAQ.What sector and industry is SGHT in?
Sight Sciences Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Sight Sciences Inc. go public?
Sight Sciences Inc. (SGHT) completed its IPO in 2021.What are analysts saying about SGHT?
Sight Sciences Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Buy with a $700.00 price target on 2026-07-28. Recent price targets range from $450.00 to $1000.00.What companies are similar to SGHT?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare SGHT side-by-side with any of them on Quantisnow.How can I track SGHT on Quantisnow?
Quantisnow aggregates Sight Sciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SGHT to receive live email and push alerts on every new disclosure.